DE60118362D1 - VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN - Google Patents

VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN

Info

Publication number
DE60118362D1
DE60118362D1 DE60118362T DE60118362T DE60118362D1 DE 60118362 D1 DE60118362 D1 DE 60118362D1 DE 60118362 T DE60118362 T DE 60118362T DE 60118362 T DE60118362 T DE 60118362T DE 60118362 D1 DE60118362 D1 DE 60118362D1
Authority
DE
Germany
Prior art keywords
present
hemostatic
selectin
disorders
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60118362T
Other languages
English (en)
Other versions
DE60118362T2 (de
Inventor
D Wagner
Patrick Andre
Daqing W Hartwell
Ingrid Hrachovinova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Disease Institute Inc
Original Assignee
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Disease Institute Inc filed Critical Immune Disease Institute Inc
Publication of DE60118362D1 publication Critical patent/DE60118362D1/de
Application granted granted Critical
Publication of DE60118362T2 publication Critical patent/DE60118362T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DE60118362T 2000-05-19 2001-05-17 VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN Expired - Fee Related DE60118362T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20573400P 2000-05-19 2000-05-19
US205734P 2000-05-19
PCT/US2001/016021 WO2001089564A2 (en) 2000-05-19 2001-05-17 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity

Publications (2)

Publication Number Publication Date
DE60118362D1 true DE60118362D1 (de) 2006-05-18
DE60118362T2 DE60118362T2 (de) 2007-05-24

Family

ID=22763420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118362T Expired - Fee Related DE60118362T2 (de) 2000-05-19 2001-05-17 VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN

Country Status (8)

Country Link
US (4) US20020031508A1 (de)
EP (1) EP1289552B1 (de)
JP (1) JP2003534291A (de)
AT (1) ATE321570T1 (de)
AU (2) AU6173501A (de)
CA (1) CA2408883A1 (de)
DE (1) DE60118362T2 (de)
WO (1) WO2001089564A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
AU2003249641B2 (en) 2002-05-16 2009-08-20 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
US20040096396A1 (en) * 2002-07-03 2004-05-20 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US8377887B1 (en) 2003-07-29 2013-02-19 Hsin-Hou Chang Methods of reducing hypoxic stress in a mammal by administering soluble P-selectin
TW200503734A (en) * 2003-07-29 2005-02-01 Hsin-Hou Chang New use of soluble p-selectin and anthrax lethal toxin
US7361644B2 (en) * 2003-11-19 2008-04-22 Glycomimetics, Inc. Specific antagonist for both E- and P-selectins
US20050187171A1 (en) * 2003-11-19 2005-08-25 Glycomimetics, Inc. Glycomimetic antagonists for both E-and P-selectins
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
US7807636B1 (en) * 2004-11-12 2010-10-05 Wisconsin Alumni Research Foundation Bovine P-selectin glycorpotein ligand-1
US20090036386A1 (en) * 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
ATE528311T1 (de) * 2005-08-09 2011-10-15 Glycomimetics Inc Glycomimetische inhibitoren des pa-il-lectins, pa-iil-lectins oder beider lectine aus pseudomonas
JP5209476B2 (ja) 2005-09-02 2013-06-12 グリコミメティクス， インコーポレイテッド ヘテロ二官能性全セレクチン阻害剤
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
EP2029164B1 (de) * 2006-06-07 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Anti-leukozyten-rekrutierungstherapie zur behandlung epileptischer anfälle
EP2074132B1 (de) 2006-10-12 2013-05-15 GlycoMimetics, Inc. Glycomimetischer ersatz für hexosen und n-acetyl-hexosamine
US20100104502A1 (en) * 2006-11-06 2010-04-29 The Regents Of The University Of Michigan Compositions and methods for detecting and treating endothelial dysfunction
EP2662091B1 (de) 2006-12-01 2018-08-22 Selexys Pharmaceuticals Corporation Anti-P-Selektin-Antikörper und Verfahren zu ihrer Verwendung für die Behandlung von Entzündungserkrankungen
CA2677747A1 (en) * 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
AU2009246166B2 (en) * 2008-05-15 2014-09-18 Tetherex Pharmaceuticals Corporation Anti-PSGL-1 antibodies and methods of identification and use
CN102088983B (zh) * 2008-06-13 2013-01-30 糖模拟物有限公司 利用选择的糖模拟化合物的血液癌症的治疗
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
CA2760292A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
PL2555789T3 (pl) * 2010-04-08 2021-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptydy hamujące pochodzące z transkryptu trem-podobnego 1 (tlt-1) i ich zastosowania
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
AU2012358150B2 (en) 2011-12-22 2017-07-20 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
EP3361254B1 (de) * 2013-12-18 2019-10-23 Siemens Healthcare Diagnostics Inc. Detektion von endothelialer erkrankung
CA2968391C (en) 2014-12-03 2022-04-26 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
WO2017127422A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
EP3497131B1 (de) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Kombination von t-zell-checkpoint-inhibitoren mit e-selectin- oder cxcr4-inhibitoren oder mit heterobifunktionellen e-selectin- wie auch cxcr4-inhibitoren
JP7069136B2 (ja) 2016-10-07 2022-05-17 グリコミメティクス， インコーポレイテッド 極めて強力な多量体ｅ－セレクチンアンタゴニスト
WO2018167119A1 (en) * 2017-03-15 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
EP3732186A1 (de) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunktionale inhibitoren von e-selektin und galectin-3
US11879012B2 (en) * 2018-03-02 2024-01-23 Peter GILLIES Method of modulating cell proliferation
CN111867601A (zh) 2018-03-05 2020-10-30 糖模拟物有限公司 用于治疗急性髓系白血病及相关病症的方法
US20190388548A1 (en) * 2018-06-26 2019-12-26 Tzu Chi University Method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2023133555A2 (en) * 2022-01-10 2023-07-13 Zilker Sciences Llc Palmitoylethanolamide treatment for covid-19-related inflammation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5605821A (en) * 1989-03-08 1997-02-25 Board Of Regents Of The University Of Oklahoma Expression control sequences of the P-selectin gene
US5026537A (en) * 1989-04-06 1991-06-25 Centocor, Inc. Methods for imaging atherosclerotic plaque
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US5807745A (en) 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
ATE169227T1 (de) 1991-09-30 1998-08-15 Biogen Inc Hemmung von gefässverengung unter verwendung von anti-padgem antikörpern.
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6033667A (en) 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
EP0668907A1 (de) * 1992-11-16 1995-08-30 Board Of Regents Of The University Of Oklahoma Glycoproteinligand für p-selection und verfahren zur dessen verwendung
US5483707A (en) * 1993-03-01 1996-01-16 Meyer; Douglas S. Self standing support structure and method
AU2191795A (en) * 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US20020040008A1 (en) * 1995-01-24 2002-04-04 Wagner Denisa D. Method for treating and preventing atherosclerosis
US5763201A (en) * 1996-02-05 1998-06-09 Emory University Flow cytometry assay for heparin-induced thrombocytopenia
CA2247115C (en) * 1996-03-01 2008-11-18 The Regents Of The University Of California Inhibition of selectin binding
US6230713B1 (en) * 1998-01-29 2001-05-15 Margaret R. Dalesandro Determining a treatment plan for patients undergoing thrombotic event by monitoring P-selectin
US6596705B1 (en) * 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US6391568B1 (en) * 1998-07-15 2002-05-21 Lionheart Technologies, Inc. Method for determining platelet reactivity in a whole blood sample
WO2000016801A1 (en) * 1998-09-21 2000-03-30 Genetics Institute, Inc. Methods of downmodulating the immune response to therapeutic proteins
US6277675B1 (en) * 1999-10-28 2001-08-21 United Microelectronics Corp. Method of fabricating high voltage MOS device

Also Published As

Publication number Publication date
US20040265311A1 (en) 2004-12-30
JP2003534291A (ja) 2003-11-18
US20050202007A1 (en) 2005-09-15
EP1289552A2 (de) 2003-03-12
WO2001089564A3 (en) 2002-05-10
EP1289552B1 (de) 2006-03-29
AU6173501A (en) 2001-12-03
CA2408883A1 (en) 2001-11-29
AU2001261735B2 (en) 2006-09-21
US20020031508A1 (en) 2002-03-14
US20080193949A1 (en) 2008-08-14
ATE321570T1 (de) 2006-04-15
US7387777B2 (en) 2008-06-17
WO2001089564A2 (en) 2001-11-29
DE60118362T2 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
DE60118362D1 (de) VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
Mei et al. Arresting dentine caries with silver diamine fluoride: what’s behind it?
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2000035473A3 (en) Methods for detection and use of differentially expressed genes in disease states
US6652840B1 (en) Bleeding control and healing aid compositions and methods of use
ATE536855T1 (de) Gewebegerüste zusamensetzungen zur behandlung von zahnerkrankungen
DE69520569D1 (de) Mittel für die behandlung von störungen des blutgerinnungsprozess
HUP0301729A2 (hu) Gyógyszer szívelégtelenség megelżzésére és kezelésére
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE431734T1 (de) Pentamidine zur behandlung von krebs
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE383870T1 (de) Behandlung von neurodegenerative krankheiten mit gpr49
DE602004026683D1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
Bayoumi et al. The effects of using hyaluronic acid on the extraction sockets
DE60042171D1 (de) Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE69302276D1 (de) Diagnostische Methode
WO2003065871A3 (en) Methods and compositions for treating hematological disorders
DE60225845D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
ATA187398A (de) Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
ATE376425T1 (de) Verfahren zur behandlung bestimmter augenkrankheiten
ATE240352T1 (de) Komplexverbindungen zur diagnose von gefässerkrankungen
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee